GlassScriptPhysician profile
John Lippelman
NPI 1134198583
$4,074.86
in general payments reported to CMS, 2019-2025
25 companies · $637 in 2025
The $637 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $148 · 2021: $530 · 2022: $678 · 2023: $945 · 2024: $583 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,164.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,170.11 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $525.63 | 2019-2025 | Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $433.57 | 2022-2025 | |
| Esperion Therapeutics, INC. | $348.73 | 2021-2025 | Nexletol |
| Abbvie INC. | $268.09 | 2022-2025 | |
| Lilly USA, LLC | $225.11 | 2022-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $143.21 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $131.75 | 2022-2025 | |
| Stryker Corporation | $131.26 | 2023 | Blueprint Patient Specific Instrumentation, Aequalis Perform Reversed |
| Novo Nordisk INC | $109.81 | 2022-2024 | Rybelsus, Ozempic |
| Kowa Pharmaceuticals America, INC. | $102.61 | 2021-2023 | Livalo, Seglentis |
| Teva Pharmaceuticals USA, INC. | $89.85 | 2019 | |
| Lucid Diagnostics INC. | $66.08 | 2023-2025 | |
| 3b Medical, INC. | $56.90 | 2024 | Luna |
| Cleerly, INC. | $46.45 | 2023 | Cleerly Labs |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $41.03 | 2021 | |
| Globus Medical, INC. | $28.10 | 2025 | Senza |
| Idorsia Pharmaceuticals US INC | $24.44 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $22.85 | 2024 | Nuzyra |
| Eisai INC. | $20.80 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $19.84 | 2019 | |
| Vanda Pharmaceuticals INC. | $19.29 | 2019 | |
| Exact Sciences Corporation | $19.26 | 2025 | Cologuard Collection Kit |
| Philips North America LLC | $19.08 | 2024 | (Ck7) Extended Holter |
| Smith+Nephew, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lippelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.